Scott Scarneo - Publications

2018- Pharmacology Duke University, Durham, NC 

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Damhofer H, Tatar T, Southgate B, Scarneo S, Agger K, Shlyueva D, Uhrbom L, Morrison GM, Hughes PF, Haystead T, Pollard SM, Helin K. TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers. Cell Death & Disease. 15: 273. PMID 38632238 DOI: 10.1038/s41419-024-06654-1  0.637
2023 Haystead T, Lee E, Cho K, Gullickson G, Hughes P, Krafsur G, Freeze R, Scarneo S. Investigation of SARS-CoV-2 individual proteins reveals the in vitro and in vivo immunogenicity of membrane protein. Scientific Reports. 13: 22873. PMID 38129491 DOI: 10.1038/s41598-023-49077-2  0.575
2023 Freeze R, Yang KW, Haystead T, Hughes P, Scarneo S. Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis. Pharmacology Research & Perspectives. 11: e01124. PMID 37564034 DOI: 10.1002/prp2.1124  0.738
2023 Bale S, Verma P, Yalavarthi B, Scarneo SA, Hughes PF, Amin MA, Tsou PS, Khanna D, Haystead TA, Bhattacharyya S, Varga J. Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis. Jci Insight. PMID 37306632 DOI: 10.1172/jci.insight.165358  0.603
2023 Scarneo S, Zhang X, Wang Y, Camacho-Domenech J, Ricano J, Hughes P, Haystead T, Nackley AG. Transforming growth factor-β-activated kinase 1 (TAK1) mediates chronic pain and cytokine production in mouse models of inflammatory, neuropathic, and primary pain. The Journal of Pain. PMID 37121498 DOI: 10.1016/j.jpain.2023.04.011  0.316
2022 Scarneo SA, Smith AP, Favret J, O'Connell R, Pickeral J, Yang KW, Ferrari G, Loiselle DR, Hughes PF, Kulkarni MM, Gargesha M, Scott B, Roy D, Haynes BF, Kwiek JJ, et al. Expression of membrane Hsp90 is a molecular signature of T cell activation. Scientific Reports. 12: 18091. PMID 36302951 DOI: 10.1038/s41598-022-22788-8  0.698
2022 Scarneo S, Hughes P, Freeze R, Yang K, Totzke J, Haystead T. Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. Acs Chemical Biology. PMID 35234444 DOI: 10.1021/acschembio.1c00788  0.693
2021 Wang Y, Scarneo SA, Kim SH, Zhang X, Chen J, Yang KW, Hughes P, Haystead T, Nackley AG. Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain. Pain. PMID 34995041 DOI: 10.1097/j.pain.0000000000002511  0.58
2020 Totzke J, Scarneo SA, Yang KW, Haystead TAJ. TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biology. 10: 200099. PMID 32873150 DOI: 10.1098/Rsob.200099  0.722
2020 Scarneo SA, Yang KW, Roques JR, Dai A, Eibschutz LS, Hughes P, Haystead TAJ. TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades. Oncotarget. 11: 1961-1970. PMID 32523651 DOI: 10.18632/Oncotarget.27606  0.346
2019 Scarneo SA, Hughes PF, Yang KW, Carlson DA, Gurbani D, Westover KD, Haystead TAJ. A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. The Journal of Biological Chemistry. PMID 31914413 DOI: 10.1074/Jbc.Ra119.011857  0.629
2019 Scarneo SA, Eibschutz LS, Bendele PJ, Yang KW, Totzke J, Hughes P, Fox DA, Haystead TAJ. Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Research & Therapy. 21: 292. PMID 31847895 DOI: 10.1186/S13075-019-2073-X  0.699
2018 Scarneo SA, Mansourati A, Eibschutz LS, Totzke J, Roques JR, Loiselle D, Carlson D, Hughes P, Haystead TAJ. Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Scientific Reports. 8: 17058. PMID 30451876 DOI: 10.1038/S41598-018-35189-7  0.689
Show low-probability matches.